Valuation: StemCell Institute Inc.

Market Cap 7.71B 48.41M 41.55M 38.99M 35.63M 67.17M 4.62B 67.46M 458M 179M 2.33B 182M 178M P/E 2026
49.6x
P/E 2027 * 70.3x
Enterprise Value 7.71B 48.41M 41.55M 38.99M 35.63M 67.17M 4.62B 67.46M 458M 179M 2.33B 182M 178M EV / Sales 2026
2.74x
EV / Sales 2027 * 2.49x
Free-Float
22.67%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week-0.52%
Current month+7.89%
1 month+5.66%
3 months+18.03%
6 months-14.03%
Current year-3.40%
1 week 761
Extreme 761
775
1 month 699
Extreme 699
775
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,005
3 years 627
Extreme 627
2,776
5 years 627
Extreme 627
3,365
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 31/05/2016
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 53 31/08/2013
Director/Board Member 81 31/05/2015
Director/Board Member 66 31/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-0.52%-23.93%-70.93% 48.81M
+1.53%-0.62%+32.45%+40.11% 119B
-0.37%+3.75%+6.06%+56.31% 92.83B
-0.42%-1.89%-3.12%+56.25% 30.13B
+0.20%+3.70%+37.13%+85.06% 26.99B
+0.85%+1.47%+52.13%+269.38% 21.89B
-0.29%+0.67%-1.64%-5.81% 22.44B
-2.13%+4.90%-6.04%+21.14% 15.27B
0.00%-0.88%-7.52%-8.94% 12.48B
+1.27%+1.20%+31.11%+78.96% 11.34B
Average -0.10%+1.51%+11.66%+52.15% 35.22B
Weighted average by Cap. +0.10%+1.05%+18.73%+59.20%

Financials

2026 2027 *
Net sales 2.87B 18.01M 15.46M 14.5M 13.26M 24.99M 1.72B 25.1M 170M 66.53M 868M 67.66M 66.18M 3.1B 19.46M 16.7M 15.67M 14.32M 26.99M 1.86B 27.11M 184M 71.86M 938M 73.08M 71.49M
Net income 180M 1.13M 970K 910K 831K 1.57M 108M 1.57M 10.68M 4.17M 54.45M 4.24M 4.15M 110M 690K 593K 556K 508K 958K 65.88M 962K 6.53M 2.55M 33.28M 2.59M 2.54M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
26/08/26 JP¥766.00 -0.78% 4,700
25/08/26 JP¥772.00 +0.65% 1,800
24/08/26 JP¥767.00 -1.03% 2,100
21/08/26 JP¥775.00 0.00% 14,900
20/08/26 JP¥775.00 +0.65% 4,300

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock